TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.
RemeGen Co., Ltd. announced that its novel bispecific antibody, RC148, has been granted Breakthrough Therapy Designation by the China National Medical Products Administration for the treatment of non-small cell lung cancer (NSCLC). This designation, based on promising Phase I/II clinical study results, will expedite the development and potential market approval of RC148, highlighting its significant clinical value and offering a new treatment option for patients with advanced NSCLC who have failed prior therapies.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in the People’s Republic of China, focusing on the development of innovative drugs for the treatment of life-threatening diseases. The company is known for its work in creating novel antibody-based therapies, particularly in the oncology sector.
Average Trading Volume: 12,019,673
Technical Sentiment Signal: Buy
Current Market Cap: HK$45.46B
See more data about 9995 stock on TipRanks’ Stock Analysis page.